Singapore-based Mesh Bio, a digital health startup transforming chronic disease management through predictive analytics, and UK-based artificial intelligence (AI)-enabled drug discovery company MultiOmic Health today announce their partnership to conduct an observational clinical study on patients with chronic metabolic disease and increased risk of complications such as chronic kidney disease.
Singapore-based healthtech startup Mesh Bio has raised USD1.8 million (SGD2.4 million) in Seed funding, led by deep tech investors Elev8.vc and Enterprise Singapore’s investment arm Seeds Capital, along with Citrine Capital and Tael Partners. The funds will be used to accelerate the rollout of Mesh Bio’s solution, DARA® – a predictive analytics and clinical workflow automation solution for healthcare providers – in Southeast Asia and Hong Kong. The funding will also support clinical partnerships and collaborations.
Mesh Bio, a Singapore-based predictive analytics digital health startup for diagnosis and management of chronic diseases, has announced today their participation in the upcoming Startup Creasphere Batch 3 accelerator program, an international collaboration set to pilot Mesh Bio’s digital solutions.